Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
neurodegenerative diseases
Biotech
Cognition's phase 2 SHIMMER results allow dementia drug to shine
The phase 2 study in dementia with Lewy bodies met its primary endpoint of safety and tolerability, Cognition said.
James Waldron
Dec 18, 2024 7:00am
GSK pays Flagship biotech $80M for preclinical neuro pact
Nov 12, 2024 6:30am
Brain stimulation slows Alzheimer's disease in one-year trial
Oct 31, 2024 6:45am
GemVax's peptide drug fails phase 2a neurodegenerative trial
Oct 29, 2024 11:28am
Booster takes off with protein degraders for neurodegeneration
Oct 10, 2024 9:25am
Potential new Alzheimer's drugs target tangles of tau
Sep 19, 2024 2:42pm